Everyone who is diagnosed with bowel cancer in the UK is tested for Lynch syndrome, an inherited cancer pre-disposition syndrome. The same is not true for womb cancer, despite the proportion of womb cancers related to Lynch syndrome being very similar.

Supported by gynaecological cancer charity The Eve Appeal, our academics are making the case that policy need to change, and all endometrial cancers be screened for Lynch syndrome – to improve womb cancer treatments, to increase early diagnoses of womb and bowel cancer, and to help more families prepare for the future.

Help us spread the word by watching and sharing our #LetsTalkLynch films, with new content released on every “Womb Wednesday” of this September’s Cancer Awareness Month.

The Faculty of Biology, Medicine and Health delivers high quality education and training for health professionals and life scientists. We have a global reputation for research with real-world impact beyond the lab.

Find out more:


https://www.bmh.manchester.ac.uk
https://www.facebook.com/bmhuom/
https://twitter.com/FBMH_UoM
https://www.instagram.com/fbmh_uom/
https://manchesterbmhstudents.wordpress.com/

Lynch syndrome (LS) is an inherited disorder that raises a person’s risk of developing colorectal, endometrial (uterine), ovarian, stomach, and other forms of cancer. Expanded screening for Lynch syndrome has been widely recommended due to the potential benefits to both patients and their family members, but has not yet been fully implemented throughout the United States. Join us for the March 21, 2017 Research to Reality cyber-seminar to learn more about Lynch syndrome, universal tumor screening, and some reflections from a National Cancer Institute hosted workshop focused on LS.

David Chambers, MSc, DPhil, will give a brief overview of the webinar and provide some key takeaways from the NCI hosted workshop, ‘Approaches to Blue Ribbon Panel Recommendations: The Case of Lynch Syndrome’, convening on February 23 and 24, 2017.

Heather Hampel, MS, LGC, will provide an overview of Lynch syndrome, current screening practices, and the benefits of universal tumor screening for LS.

Greg Feero, MD, PhD, will discuss some of the issues that must be addressed to improve the identification and management of individuals at risk for hereditary cancer syndromes in primary care settings, and how his pilot project is approaching this issue.

Debra Duquette, MS, CGC, will share ways in which the Michigan Department of Health and Human Services Cancer Genomics Program promotes awareness of and best practices surrounding Lynch syndrome. She will also describe the Lynch Syndrome Screening Network, a resource for health systems interested in implementing routine LS screening.

The presenters will share their experiences working with the Lynch Syndrome Screening Network and reflect on their experiences at the NCI-hosted workshop. The final part of the webinar will offer an opportunity for participants to engage with the presenters. We encourage you to share your own experiences and thoughts!

An archive of the cyber-seminar may be accessed at: https://researchtoreality.canc....er.gov/cyber-seminar

Learn about our dedicated Lynch Syndrome Center - https://www.dana-farber.org/lynchsyndrome Dana-Farber genetic counselors, Sam Stickevers, LGC, and Sarah Cochrane, LGC, give an overview of the genetics of Lynch syndrome, genetic testing and questions surrounding test results for Lynch syndrome.

Find out more about our Tumor/Germline Testing at https://www.ambrygen.com/

In 2017, Ambry Genetics was the first commercial laboratory to launch paired Tumor testing and Germline testing for Lynch Syndrome.

Learn more: http://ow.ly/SrWK50zgrTy
Microsatellite instability (MSI) is a hallmark of certain types of cancer. The presence and level of MSI in a tumor sample can offer insight into tumor pathology and inform treatment options, making the evaluation of tumor samples for MSI an important part of understanding the cause and management of many types of cancer. As Dr. Paul Walker, Chief Medical Officer at Circulogene, explains in this video, MSI testing is critically important for solid-tumor patients in particular, for whom the outcome of this test can mean the difference between ineffective and effective standard treatments.

Hereditary Colon Cancer is very common. It actually accounts for 5-10% of all colon cancers. We know the most common hereditary cause of colon cancer is a condition called Lynch Syndrome, which occurs in about 1 in 400 individuals in the U.S.

Learn more at http://www.ambrygen.com/

It is estimated that greater than 90% of individuals with lynch syndrome are currently undiagnosed. Therefore, screening of all colon and endometrial cancers may help increase the detection of lynch syndrome in general population.

Learn more at http://www.ambrygen.com/

Learn more about our comprehensive Lynch Syndrome Center at https://www.dana-farber.org/lynchsyndrome
Keynote Speaker Professor Sir John Burn, MD, Professor of Clinical Genetics at Newcastle University, and Chair of Newcastle Hospitals in the NHS Foundation Trust, from Newcastle upon Tyne, UK, delivers the Keynote Address at the 4th Annual 2019 LYNKED IN Lynch Syndrome Conference, on the affects of aspirin in reducing cancer risk in patients with Lynch syndrome.